Research
Hormonal
Peptide YY (PYY) is a satiety signal released from the gut after meals that inhibits food intake and promotes weight loss, with effects observed in both lean and obese humans.
PYY is a hormone released by the gut after eating, especially when lipids and carbohydrates are present in the lower intestine. It signals the brain to stop eating. While its effect is modest, it is a key natural mechanism for satiety that works even in obese individuals.
GoodSupportsHIGH confidence
Peripheral administration of this hormone inhibits food intake and causes weight loss [72, 73]. ... the satiety effect of PYY(3-36) is comparatively modest but, importantly, is observed also in humans, including obese patients [73, 78].
Why this rating
Based on human studies and replication of effects.
Source
Brain regulation of food intake and appetite: molecules and networks
Christian Broberger · Journal of Internal Medicine · 2005
DOI 10.1111/j.1365-2796.2005.01553.x
narrative_reviewCited 246×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Genetic deficiency of leptin causes severe obesity in mice, which is completely reversed by leptin replacement therapy, demonstrating that leptin is essential for maintaining body weight homeostasis.Strong
- Bariatric surgery induces weight loss primarily through the suppression of ghrelin, a hunger-stimulating hormone, rather than solely through malabsorption.Good
- Ghrelin is the first gut hormone shown to stimulate food intake, and its levels peak before meals, acting as a hunger signal.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →